MIRA stock forecast, quote, news & analysis
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders... Show more
MIRA Pharmaceuticals (MIRA) Stock Analysis: Phase 1 Milestone Fuels Pipeline Momentum
Key Takeaways
- MIRA Pharmaceuticals advances Ketamir-2 Phase 1 trial to final cohort, with 50 volunteers dosed and no serious adverse events reported.
- Stock has traded in a narrow range around $1.15-$1.25 in recent weeks amid clinical progress, down over 20% year-to-date.
- Plans for Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN) targeted for Q2 2026, with Fast Track pursuit.
- Pipeline includes MIRA-55 for pain and SKNY-1 for obesity/nicotine addiction, bolstering diversification.
- Market cap hovers near $48 million, reflecting clinical-stage biotech volatility and investor caution.
Current Market Snapshot
MIRA Pharmaceuticals stock has navigated volatile sessions in recent weeks, oscillating within a tight band amid broader biotech sector pressures. Trading volumes remain moderate, underscoring limited liquidity typical for micro-cap clinical developers. The share price reflects ongoing Phase 1 execution for lead candidate Ketamir-2 while contending with year-to-date declines exceeding 20 percent. Investor sentiment balances trial advancements against funding needs and competitive dynamics in neuropathic pain therapeutics, positioning MIRA as a speculative play in neuroscience innovation.
Recent Developments Driving MIRA Price Action
MIRA Pharmaceuticals, a clinical-stage biopharma focused on oral therapies for neuropathic pain, neuropsychiatric disorders, and metabolic conditions, has centered recent activity on its lead asset, Ketamir-2, an oral ketamine analog targeting NMDA receptors without scheduling risks. The past 30 days featured a pivotal update on February 3, 2026, announcing initiation of dosing in the final cohort of the Phase 1 multiple ascending dose (MAD) trial. With 50 healthy volunteers already dosed and only six remaining, the randomized, double-blind, placebo-controlled study has shown no serious adverse events, supporting safety and tolerability for pharmacokinetics assessment. This milestone positions completion by end-Q1 2026, paving the way for Phase 2a in chemotherapy-induced peripheral neuropathy (CIPN), an area lacking FDA-approved treatments affecting millions.
The announcement elicited a muted market response, with shares dipping about 1.65% that day, indicative of "buy the rumor, sell the news" dynamics in biotech. Price action since has stabilized around $1.16, down from mid-January levels near $1.45, amid lower volumes and YTD losses of 23%. Broader pressures include biotech index weakness and macroeconomic caution on small-caps, though no new financings or dilutions were filed recently. MIRA plans FDA submission for Phase 2a protocol post-Phase 1, eyeing Fast Track designation given CIPN's unmet need. Additional catalysts include Phase 1 data presentation at the American Association for Cancer Research (AACR) meeting in April 2026 and partnering outreach at BIO Partnering Summit in March.
No earnings or major regulatory updates emerged in the period, with the latest 10-Q reflecting ongoing cash burn typical for clinical operations. Earlier pipeline momentum from 2025—such as MIRA-55 preclinical data outperforming morphine and SKNY-1 acquisition for obesity—continues to underpin sentiment, though recent price softness ties to trial anticipation digestion rather than setbacks. Analyst coverage remains sparse, with prior Buy initiations from Rodman & Renshaw and Ascendiant, but no fresh changes. Overall, developments affirm execution amid volatility, with stock sensitivity heightened ahead of topline readout.
2026 Outlook and Key Factors to Monitor
MIRA enters 2026 with Phase 1 Ketamir-2 topline data expected imminently, setting the stage for Phase 2a launch in CIPN pending FDA feedback. Success here could validate oral delivery advantages over injectables, targeting a high-unmet-need oncology supportive care market. Investors should track Fast Track progress, AACR presentation reception, and BIO partnering outcomes for validation or deals. Pipeline breadth via MIRA-55 (IND for inflammatory pain) and SKNY-1 (obesity/nicotine, CMC optimization) offers diversification amid neuroscience tailwinds like non-opioid pain therapies.
Risks include trial delays, funding requirements given ~$48 million market cap and negative EPS, and competition from established players. Regulatory hurdles, manufacturing scale-up, and macro biotech funding environment warrant scrutiny. Balanced monitoring of clinical milestones, cash runway via SEC updates, and sector peers will inform positioning through the year.
MIRA's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for MIRA moved out of overbought territory on May 28, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MIRA as a result. In of 47 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for MIRA turned negative on June 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at .
MIRA moved below its 50-day moving average on June 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MIRA crossed bearishly below the 50-day moving average on June 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MIRA broke above its upper Bollinger Band on May 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MIRA entered a downward trend on May 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRA advanced for three days, in of 104 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.281) is normal, around the industry mean (19.503). MIRA has a moderately low P/E Ratio (0.000) as compared to the industry average of (25.855). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.650). MIRA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.032). MIRA's P/S Ratio (0.000) is slightly lower than the industry average of (3.885).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MIRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 66, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsMajor